Opsona Therapeutics Ltd.
🇮🇪Ireland
- Country
- 🇮🇪Ireland
- Ownership
- Private
- Established
- 2004-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.opsona.com
Follow up Protocol to the Phase I/II Study of OPN-305 in Second-line or Third-line Lower Lower Risk Myelodysplastic Syndrome
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2019-01-28
- Lead Sponsor
- Opsona Therapeutics Ltd.
- Target Recruit Count
- 14
- Registration Number
- NCT03337451
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
A Phase I/II Study of OPN-305 in Second-line Lower Risk Myelodysplastic Syndrome
- First Posted Date
- 2015-02-16
- Last Posted Date
- 2019-01-28
- Lead Sponsor
- Opsona Therapeutics Ltd.
- Target Recruit Count
- 96
- Registration Number
- NCT02363491
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
- First Posted Date
- 2013-02-20
- Last Posted Date
- 2017-02-16
- Lead Sponsor
- Opsona Therapeutics Ltd.
- Target Recruit Count
- 252
- Registration Number
- NCT01794663
- Locations
- 🇬🇧
Research Site, Newcastle upon Tyne, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath